Our analysis reveals significant increase in the expression of NKG2D in the CD56bright and CD56dim NK subsets with higher UPDRS scores in PD patients compare to HC (Fig. 3), providing valuable insights into the immunomodulatory and cytotoxicity contexts that NK cells may mediate in PD patients. Here, KLRK1 is linked to Parkinson disease.